Second-generation Drug-eluting Stents in Diabetes

Inclusion Criteria(must meet all): * Patients ≥18 years who understands the nature of the study and provides written informed consent. * Diagnosis of diabetes according to the American Diabetes Association diagnostic criteria (\*) * Documented silent ischemia, stable angina, unstable angina, or myocardial infarction (with or without ST elevation). * At least one de novo coronary lesion with stenosis of more than 50% in a vessel with a reference vessel diameter of 2.25 to 4.5 mm by visual estimation. Coronary anatomy is suitable for PCI (patients with potential CABG indication should be eligible for PCI after a multidisciplinary evaluation in a Heart Team). Exclusion Criteria: * Cardiogenic shock or resuscitation * Comorbidity with anticipated life expectancy to 24 months * Inability to consent due to mechanical ventilation * Pregnant female patient * Conditions that could preclude a minimal of 1 month of DAPT (such as, but not limited to: severe liver failure, platelet count \<100,000 cells/mm3, recent gastrointestinal bleeding or history of bleeding diathesis or coagulopathy) * Contraindication or known allergy to aspirin, heparin, P2Y12 inhibitors, cobalt and/or chromium metal alloys, sirolimus or derivates, polyurethane, or contrast media (for contrast-media allergy, patients that might be safely and adequately pre-medicated should be allowed to enter the study). * Currently enrolled in another clinical trial.